Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152
Authors:
- Pragya D YadavPragya D Yadav
- Rima R SahayRSRima R Sahay
- Gajanan SapkalGSGajanan Sapkal
- Dimpal NyayanitDNDimpal Nyayanit
- Anita M SheteASAnita M Shete
- Gururaj DeshpandeGDGururaj Deshpande
- Deepak Y PatilDPDeepak Y Patil
- Nivedita GuptaNGNivedita Gupta
- Sanjay KumarSKSanjay Kumar
- Priya AbrahamPAPriya Abraham
- Samiran PandaSPSamiran Panda
- Balram BhargavaBBBalram Bhargava
Open Access
- 28 September 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (8)
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern, was associated with the second wave of pandemic in India during March–May 2021. Delta variant has outpaced the other two sub-lineages Kappa (B.1.617.1) and B.1.617.3 and was responsible for 90% of the cases reported in India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4Keywords
All Related Versions
Funding Information
- Indian Council of Medical Research
This publication has 6 references indexed in Scilit:
- Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of IndiaViruses, 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantNew England Journal of Medicine, 2021
- Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individualsJournal of Travel Medicine, 2021
- Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/CovaxinJournal of Travel Medicine, 2021
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialThe Lancet Infectious Diseases, 2021
- Vaccine Breakthrough Infections with SARS-CoV-2 VariantsNew England Journal of Medicine, 2021